[go: up one dir, main page]

PE20160847A1 - Nuevo compuesto para el tratamiento de hipoglicemia severa - Google Patents

Nuevo compuesto para el tratamiento de hipoglicemia severa

Info

Publication number
PE20160847A1
PE20160847A1 PE2016000771A PE2016000771A PE20160847A1 PE 20160847 A1 PE20160847 A1 PE 20160847A1 PE 2016000771 A PE2016000771 A PE 2016000771A PE 2016000771 A PE2016000771 A PE 2016000771A PE 20160847 A1 PE20160847 A1 PE 20160847A1
Authority
PE
Peru
Prior art keywords
treatment
severe hypoglycemia
new compound
refers
compound
Prior art date
Application number
PE2016000771A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Lili Guo
Robert Chadwick Cummins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52273565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160847(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20160847A1 publication Critical patent/PE20160847A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Se refiere a un compuesto peptidico que comprende la secuencia de aminoacidos como se describe en la SEC ID NO: 2. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto, el cual proporciona actividad similar como glucagon humano, siendo util en el tratamiento de hipoglicemia tanto aguda como severa
PE2016000771A 2013-12-18 2014-12-11 Nuevo compuesto para el tratamiento de hipoglicemia severa PE20160847A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917716P 2013-12-18 2013-12-18

Publications (1)

Publication Number Publication Date
PE20160847A1 true PE20160847A1 (es) 2016-09-10

Family

ID=52273565

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000771A PE20160847A1 (es) 2013-12-18 2014-12-11 Nuevo compuesto para el tratamiento de hipoglicemia severa

Country Status (22)

Country Link
US (1) US20160311882A1 (es)
EP (1) EP3083667A1 (es)
KR (1) KR20160075826A (es)
CN (1) CN105829340A (es)
AP (1) AP2016009267A0 (es)
AR (1) AR098615A1 (es)
AU (1) AU2014366425B2 (es)
BR (1) BR112016010635A2 (es)
CA (1) CA2930596A1 (es)
CR (1) CR20160227A (es)
DO (1) DOP2016000142A (es)
EA (1) EA201690966A1 (es)
HK (1) HK1224305A1 (es)
IL (1) IL245491A0 (es)
MA (1) MA39110B1 (es)
MX (1) MX2016007988A (es)
PE (1) PE20160847A1 (es)
PH (1) PH12016501183A1 (es)
SG (1) SG11201604237PA (es)
TN (1) TN2016000208A1 (es)
TW (1) TW201609128A (es)
WO (1) WO2015094876A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
EP3921336B1 (en) 2019-02-05 2023-03-01 Eli Lilly And Company Glucagon analog agonists and methods of using the same
CN113677702A (zh) 2019-04-01 2021-11-19 诺和诺德股份有限公司 针对利拉鲁肽的抗体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628063T3 (es) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
CA2713348C (en) * 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
RU2560254C2 (ru) * 2008-06-17 2015-08-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ И СТАБИЛЬНОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМИ ЗНАЧЕНИЯМИ Ph
US8703701B2 (en) * 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
LT2718318T (lt) * 2011-06-10 2018-10-25 Hanmi Science Co., Ltd. Nauji oksintomodulino dariniai ir farmacinė kompozicija, apimanti šiuos darinius, nutukimo gydymui
EP2729493B1 (en) * 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour

Also Published As

Publication number Publication date
AR098615A1 (es) 2016-06-01
PH12016501183A1 (en) 2016-07-25
SG11201604237PA (en) 2016-07-28
MA39110A1 (fr) 2017-09-29
DOP2016000142A (es) 2016-07-15
TW201609128A (zh) 2016-03-16
CN105829340A (zh) 2016-08-03
MA39110B1 (fr) 2018-04-30
AU2014366425A1 (en) 2016-05-26
KR20160075826A (ko) 2016-06-29
AU2014366425B2 (en) 2016-12-08
IL245491A0 (en) 2016-06-30
EA201690966A1 (ru) 2016-12-30
AP2016009267A0 (en) 2016-06-30
BR112016010635A2 (pt) 2017-12-05
EP3083667A1 (en) 2016-10-26
CA2930596A1 (en) 2015-06-25
TN2016000208A1 (en) 2017-10-06
MX2016007988A (es) 2016-09-09
WO2015094876A1 (en) 2015-06-25
US20160311882A1 (en) 2016-10-27
CR20160227A (es) 2016-07-12
HK1224305A1 (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
CY1121114T1 (el) Αγωνιστες γλυκαγονης/glp-1 για τη θεραπεια της παχυσαρκιας
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
PE20180449A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
MX2017007641A (es) Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas.
CL2016001405A1 (es) A peptide mixture
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
PH12014501702A1 (en) Imidazopyrrolidinone compounds
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA201692271A1 (ru) Терапевтически активные соединения и способы их применения
CL2013003454A1 (es) Composicion farmacéutica para prevenir o tratar diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
UY36920A (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral
AR100365A1 (es) Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида

Legal Events

Date Code Title Description
FD Application declared void or lapsed